{
  "context": {
    "rules": [
      "Rule1: Provided that the facility loses its license, then it does not receive a fine.",
      "Rule2: If the facility exports to Country A, then when it fails inspection, the drug contains plant extracts.",
      "Rule3: The facility exports to Country A or to Country B.",
      "Rule4: If the facility merges with a competitor, then it rebrands.",
      "Rule5: If the facility merges with a competitor, then it restructures.",
      "Rule6: The facility merges with a competitor, or if it is audited, then it is approved by the FDA.",
      "Rule7: Provided that the facility produces a drug, then it is approved by the FDA.",
      "Rule8: If the facility restructures, then it does not rebrand.",
      "Rule9: When the drug contains plant extracts, then the facility produces the drug.",
      "Rule10: If the drug is tested in a financial product, then it contains plant extracts.",
      "Rule11: The facility uses an organic process or a synthetic process.",
      "Rule12: If the facility uses a synthetic process, then should it fail inspection, the drug is not contaminated.",
      "Rule13: If the facility receives government funding, then it complies with regulations.",
      "Rule14: Should it not be the case that compliance with regulations implies that using an organic process leads to non-contamination upon failed inspection, then the facility receives a fine.",
      "Rule15: If compliance with regulations does not result in the organic process ensuring non-contamination upon failed inspection, then the facility loses its license.",
      "Rule16: If exporting to Country B does not imply that upon failed inspection the drug contains plant extracts, then the drug is banned in Country B.",
      "Rule17: Should exporting to Country B not lead to the drug containing plant extracts upon failed inspection, then the drug is not banned in Country B.",
      "Rule18: If the failure of inspection not leading to drug production does not imply the drug fails the safety check, then the drug is fast-tracked.",
      "Rule19: Provided that the failure of inspection not leading to drug production does not result in the drug failing the safety check, then the drug is not fast-tracked.",
      "Rule20: If the failure of inspection does not lead to drug production, then the drug passes the safety check.",
      "Rule21: If the failure of inspection does not lead to testing in a financial product, then the financial product is profitable.",
      "Rule22: Provided that the failure of inspection does not imply testing in a financial product, then the financial product is not profitable.",
      "Rule23: If the facility fails inspection, then it is audited.",
      "Rule24: If the facility fails inspection, then the drug is contaminated.",
      "Rule25: Provided that the facility fails inspection, then it is not approved by the FDA."
    ],
    "facts": [
      "Fact1: The facility receives government funding."
    ]
  },
  "question": "The facility passes inspection."
}